|1.||Wang, J-X: 1 article (03/2008)|
|2.||Tang, W: 1 article (03/2008)|
|3.||Zuo, J-P: 1 article (03/2008)|
|4.||Wan, J: 1 article (03/2008)|
|5.||Zhou, R: 1 article (03/2008)|
|6.||Li, Y: 1 article (03/2008)|
|7.||Zhang, Y: 1 article (03/2008)|
|8.||Yang, Y-F: 1 article (03/2008)|
|9.||Shi, L-P: 1 article (03/2008)|
|10.||He, Pei-Lan: 1 article (06/2007)|
03/01/2008 - "In this study, we evaluate preventive and therapeutic effect of SM905 on collagen-induced arthritis (CIA) in DBA/1 mice, and investigate its mechanisms both in inflammatory and autoimmune aspects of the disease. "
03/01/2008 - "The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses."
|3.||Immune System Diseases (Immune Disorders)
03/01/2008 - "In established arthritis, SM905 profoundly inhibited disease progression, reduced IL-17A and RORgamma t mRNA expression, and suppressed pro-inflammatory mediator expression in arthritic joints. "
03/01/2008 - "Oral treatment with SM905 delayed disease onset, reduced arthritis incidence and severity, and suppressed the enhanced expression of pro-inflammatory cytokines, chemokines and chemokine receptors in draining lymph nodes. "
|2.||Interleukin-17 (Interleukin 27)
|6.||Messenger RNA (mRNA)